Snowden Capital Advisors’s iRadimed IRMD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$310K Sell
3,217
-1,045
-25% -$105K 0.01% 1010
2025
Q4
$415K Sell
4,262
-439
-9% -$37.7K 0.01% 903
2025
Q3
$335K Sell
4,701
-176
-4% -$11.7K 0.01% 971
2025
Q2
$292K Sell
4,877
-55
-1% -$3.01K 0.01% 1017
2025
Q1
$259K Buy
4,932
+761
+18% +$42.8K 0.01% 1048
2024
Q4
$229K Buy
+4,171
New +$219K 0.01% 1100

Other funds holding IRMD

Snowden Capital Advisors's IRMD Position: Q1 2026 in Review

Snowden Capital Advisors reduced its iRadimed (IRMD) stake by 25% in Q1 2026, selling an estimated $105K and leaving 3,217 shares worth $310K. The position accounts for 0.01% of the portfolio, ranked #1010.

Snowden Capital Advisors first reported a position in IRMD in Q4 2024 and has held it in 6 quarters since. The position peaked at $415K in Q4 2025. 228 funds tracked by Wall St. Rank hold IRMD as of Q1 2026.

  • Snowden Capital Advisors held 3,217 shares of iRadimed worth $310K as of Q1 2026.
  • Snowden Capital Advisors sold 1,045 iRadimed shares in Q1 2026, an estimated $105K.
  • iRadimed made up 0.01% of Snowden Capital Advisors's portfolio in Q1 2026, its #1010 holding.
  • Snowden Capital Advisors first reported a position in iRadimed in Q4 2024 and has held it in 6 quarters since.
  • Snowden Capital Advisors's iRadimed position peaked at $415K in Q4 2025.
  • 228 funds tracked by Wall St. Rank held iRadimed as of Q1 2026.

Based on Snowden Capital Advisors's 13F filing for Q1 2026, filed 15 May 2026.